Project description
Novel rapid antibiotic susceptibility testing for bacterial sepsis
Sepsis is a life-threatening condition that develops as a reaction to infection with millions of cases and deaths worldwide. Patients with sepsis require emergency antibiotic therapy to prevent disease progression and reduce mortality. The current standard antibiotic susceptibility testing (AST) takes too long to be efficient in sepsis cases. Swiss Resistell AG developed a breakthrough AST technology that delivers diagnostic results in less than 2 h instead of the current 24-48 h. The EU-funded RAPID-SEP-AST project will accelerate commercialization and support final market-critical proof of efficiency through a multicentre performance evaluation study. It will ultimately allow the rapid introduction of this testing in Europe and then globally through leading global distributors.
Objective
SEPSIS is a life-threatening reaction to infection with 48.9 million cases and 11 million deaths worldwide, 700.000 of those in the EU yearly. In epidemic-like situations such as COVID-19, SEPSIS is prevalent in >60% of the admitted patients and all non-survivors had SEPSIS. SEPSIS patients require immediate antibiotic therapy to prevent disease progression and reduce mortality. Therefore, clinicians administer empirically broad-spectrum antibiotics, which save lives but also lead to inappropriate treatments in up to 40% of cases. To identify the best antibiotic and dosage for each patient, clinicians in Acute Care and ICUs need to run diagnostics to identify both the pathogen causing the infection but test several antibiotics to find the specifically treating the infection. Antibiotic susceptibility testing takes too long to be useful in SEPSIS cases. Resistell, a Deep-Tech SME, has a breakthrough AST technology delivers AST diagnostic results in less than 2h instead of the current 24-48h. Clinicians around the world using RAPID-SEP-AST will for the first time select personalised antibiotic therapies to SEPSIS patients in the same day, increasing the success rate of treatment and reducing hospitalisation time and costs. This EIC project will accelerate RAPID-SEP-AST industrialisation, finalise CE-IVD approval and support market-critical proof of efficiency in a multicentre performance evaluation study at KOLs. RAPID-SEP-AST will allow rapid Resistell scale-up first in Europe using its strong network of EU distributors and then globally through leading global distributors. Resistell’s is a Women-Led Company (Danuta Cichocka CEO) with a strong cross-functional team of engineers, microbiologists, data scientists and serial entrepreneurs, supported by experienced Board of Directors and Scientific Advisors.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences sociology demography mortality
- social sciences economics and business business and management entrepreneurship
- medical and health sciences health sciences infectious diseases RNA viruses coronaviruses
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME - SME instrument
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
4132 Muttenz
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.